Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22296139 | 0.89 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL11917195 | 0.86 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL29061268 | 0.83 | CYP3A4 (0.36) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL11913027 | 0.82 | CES2 (0.40) | CYP3A4CYP2C9CYP2C19LMNAHTT | |
| SCHEMBL20903514 | 0.80 | GAA (0.40) | CYP3A4CYP2C9CYP2C19KDM4E | |
| SCHEMBL14405706 | 0.78 | CES2 (0.40) | CYP2C9MAPTKDM4E | |
| SCHEMBL16408541 | 0.78 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL18650595 | 0.76 | MAP4K4 (0.38) | — | |
| SCHEMBL15584523 | 0.76 | SLC22A12 (0.39) | CYP3A4CYP2C19SCN9AMEN1LMNA | |
| SCHEMBL14332118 | 0.76 | CYP3A4 (0.43) | CYP3A4LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116675672-A | New preparation method of antifungal medicine | 北京康立生医药技术开发有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-116675672-A | New preparation method of antifungal medicine | 北京康立生医药技术开发有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116675672-A | New preparation method of antifungal medicine | 北京康立生医药技术开发有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-10745378-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3119745-B1 | ANTIFUNGAL COMPOUND PROCESS | MYCOVIA PHARMACEUTICALS INC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10392365-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190161469-A1 | Antifungal Compound Process | MYCOVIA PHARMACEUTICALS INC (US) | 2019-05-30 | — | — | US | disclosed |
| US-20190161470-A1 | Antifungal Compound Process | MYCOVIA PHARMACEUTICALS INC (US) | 2019-05-30 | — | — | US | disclosed |
| US-10196375-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10173998-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10000465-B2 | Antifungal compound process | Mycovia Pharmaceuticals, Inc. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170088539-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-03-30 | — | — | US | disclosed |
| US-20170081310-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-03-23 | — | — | US | disclosed |
| WO-2015143172-A1 | ANTIFUNGAL COMPOUND PROCESS | VIAMET PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015143142-A1 | ANTIFUNGAL COMPOUND PROCESS | VIAMET PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015143180-A1 | ANTIFUNGAL COMPOUND PROCESS | VIAMET PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392365-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-10000465-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-10745378-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-10173998-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-20170081310-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-20170088539-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-20190161470-A1 | Antifungal Compound Process | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-20190161469-A1 | Antifungal Compound Process | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
| US-10196375-B2 | Antifungal compound process | ERG28, DPM1, CYP51A1 | CYP3A4 19/4885CYP2C9 307/4885CYP2C19 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.